Published on 29/11/2025

Controls & Blanks in Spiking Studies: Catching False Positives

In the realm of biopharmaceuticals, ensuring the safety and efficacy of therapeutics is paramount. Viral clearance validation (VCV) stands as a critical aspect, particularly in spiking studies employed within closed systems and single-use systems. This article serves as a comprehensive step-by-step tutorial guide detailing the necessary controls and blanks required to detect false positives during spiking studies, with particular reference to regulatory expectations set forth by bodies such as the FDA, EMA, MHRA, and aligned with ICH Q5A(R2) guidelines.

Understanding the Importance of Viral Clearance Validation

Viral clearance validation is essential for the safety of biologics, especially Advanced Therapy Medicinal Products (ATMPs). The goal is to minimize or eliminate the risk of transmitting viruses present in raw materials or introduced through the manufacturing process. Spiking studies are integral to this validation procedure, as they simulate worst-case scenarios to assess how effectively a given process can remove or inactivate viruses.

Regulatory agencies emphasize the need for rigorous validation protocols to ensure that the final product is free from viral contaminants. For this purpose, both controls and blanks must be strategically implemented. Through controls, researchers can ensure that the process operates under defined parameters, while blanks help identify any extraneous signals that could lead to false positives in test results.

Step 1: Defining Objectives for the Spiking Study

The first step in conducting a spiking study is to define clear objectives. These objectives should guide the overall design of the experiment and address specific aspects such as:

• Determining the type of viruses to be used, based on the risk assessment of starting materials.
• Establishing the target viral load that simulates worst-case conditions.
• Identifying the manufacturing process steps that will be assessed for viral clearance.

It’s essential to document these objectives carefully, as they will form the basis of your validation study design. An understanding of potency and identity Critical Quality Attributes (CQAs) is crucial here, as they provide insights into how the viral clearance capacity may affect product quality.

Step 2: Selecting the Appropriate Viral Challenge

Selecting a suitable viral challenge is critical for the study’s success. The choice should balance safety and regulatory compliance with the need for effective inactivation or removal of viruses. When selecting the viral agent, consider the following factors:

• Representative Nature: Choose viruses that mimic potential contaminants in your raw materials. This typically includes enveloped and non-enveloped viruses.
• Classification: Ensure that the selected viruses are classified safely for laboratory handling.
• Persistence: Assess the challenge virus’s persistence under the processing conditions expected in the manufacturing environment.

These factors directly influence the design of the study and help in tailoring the parameters under which the study will be conducted. Understanding the characteristics of the viruses aids in aligning with guidelines stipulated in ICH Q5A(R2).

Step 3: Designing Controls and Blanks

The backbone of any scientific validation study is the proper design of controls and blanks. In spiking studies, implementing adequate controls is essential to differentiate between genuine results and false positives. There are several types of controls and blanks to consider:

• Positive Controls: Samples that contain the known virus concentration to validate the detection method’s effectiveness.
• Negative Controls: Samples that contain no viral load to establish baseline readings for detection sensitivity.
• Process Controls: Monitoring specific steps in the purification process to evaluate the reductions in viral load effectively.

In addition to these measures, both closed system and single-use system validation requires meticulous attention to the equipment and manufacturing processes involved to ensure compliance with regulatory standards such as Aseptic Controls Annex 1.

Step 4: Implementing the Testing Protocol

Once controls and blanks have been established, it is time to implement the testing protocol. The testing protocol should comprehensively outline how the spiking study will be executed. Key elements to include are:

• Sample Preparation: Procedures for spiking the viral challenge into the test material.
• Testing Procedures: Details on how samples will be processed, including dilution or filtration methods.
• Analytical Methods: Choose methods that are validated for detecting and quantifying viral loads, which may include quantitative PCR or cell-culture assays.

Following the protocol meticulously ensures that the results obtained are reliable and reproducible. This level of detail will form part of the validation documents and presentations required by regulatory bodies.

Step 5: Data Analysis and Interpretation

The analysis of data gathered during spiking studies should be scrutinized for both positive and negative controls, along with blanks, to assess for false positives. The framework for this data analysis should focus on:

• Numerical Values: Compare the virus concentrations between spiked tests and controls to determine the efficacy of the viral clearance process.
• Statistical Methods: Utilize statistical techniques to evaluate the significance of the findings. This may include using confidence intervals and statistical power analysis to ensure robust conclusions.
• Qualitative Assessments: Consider biological activity and product integrity, ensuring the product meets all defined criteria.

Any discrepancies observed must prompt further investigation into potential sources of false positives. This could involve reviewing sampling techniques, the integrity of the analytical approach, and the conditions under which the testing is performed.

Step 6: Documentation and Compliance Considerations

Maintaining thorough documentation throughout the spiking study is vital for demonstrating compliance with relevant regulatory guidelines such as those set forth by the FDA, EMA, and MHRA. This documentation should include:

• Study Protocol: Document every aspect of the study—objectives, methodology, controls, and results.
• Compliance Records: Maintain records that link the validation effort to regulatory expectations and quality systems in place.
• Final Reports: Create a comprehensive report on the outcomes of the study detailing methods, data analysis, and conclusions.

Documentation serves as the backbone of regulatory submissions and provides an invaluable reference for future studies. Emphasis should be placed on the chain of identity custody (COI) and chain of custody (COC), ensuring that all materials and samples are traceable and accountable throughout the study.

Conclusion: Ensuring Robust Viral Clearance Validation

In summary, the complexity of viral clearance validation necessitates a structured approach to conducting spiking studies, particularly in closed and single-use systems. By defining precise objectives, selecting appropriate viral challenges, and establishing robust controls and blanks, professionals can effectively catch false positives during testing.

Every step from data analysis to compliance documentation strengthens the reliability of the results, thereby securing product safety and efficacy. It is imperative to uphold these rigorous standards in order to meet the expectations of regulatory authorities such as the FDA and EMA, ensuring that therapeutic products are safe for patient use.

Ultimately, this comprehensive tutorial serves as a practical guide for pharmaceutical professionals engaged in viral clearance validation and highlights the critical importance of precision in experimental design and execution.